Bayer Inc. v. Dr. Reddy's Laboratories Ltd., 2019 FC 1408
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2019 FC 1408 |
| Date | 12 November 2019 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
5 practice notes
-
Canadian Patent Law: 2019 Year In Review
...the PM(NOC) Regulations involving the same patent(s) and innovator parties can be de facto consolidated (2019 FC 191, 2019 FC 1039 and 2019 FC 1408). In the result, the Court ruled that four proceedings that were all commenced within six months of each other were to proceed via a common val......
-
Federal Court Refuses To Allow Fifth Generic To Join Common Trial On Validity
...the same judge, within its 24-month period. The Court declined to award costs. The case is Bayer Inc. v. Dr. Reddy's Laboratories Ltd., 2019 FC 1408. About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial i......
-
Federal Court Dismisses Motion For A Fifth Generic To Be Added To Rivaroxaban Trial Of Common Issues Under PMNOC Regulations
...that the invalidity issues it raised be heard together with the trial against the first four generic manufacturers: Bayer v Dr. Reddy's, 2019 FC 1408. Prothonotary Tabib held that the circumstances were different from the previous motions. The Court stated that the addition of another party......
-
Federal Court dismisses motion for a fifth generic to be added to rivaroxaban trial of common issues under PMNOC Regulations
...that the invalidity issues it raised be heard together with the trial against the first four generic manufacturers: Bayer v Dr. Reddy’s, 2019 FC 1408. Prothonotary Tabib held that the circumstances were different from the previous motions. The Court stated that the addition of another party......
Request a trial to view additional results
1 cases
-
Teve Canada Limited v. Bayer et al., 2020 FCA 86
...on December 11, 2020, are invalid. [5] I also note that on November 12, 2019, in Bayer Inc. v. Dr. Reddy’s Laboratories Ltd., 2019 FC 1408 [Dr. Reddy’s], the Prothonotary dismissed a motion brought by another pharmaceutical generic for an order directing that the trial o......
4 firm's commentaries
-
Canadian Patent Law: 2019 Year In Review
...the PM(NOC) Regulations involving the same patent(s) and innovator parties can be de facto consolidated (2019 FC 191, 2019 FC 1039 and 2019 FC 1408). In the result, the Court ruled that four proceedings that were all commenced within six months of each other were to proceed via a common val......
-
Federal Court Refuses To Allow Fifth Generic To Join Common Trial On Validity
...the same judge, within its 24-month period. The Court declined to award costs. The case is Bayer Inc. v. Dr. Reddy's Laboratories Ltd., 2019 FC 1408. About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial i......
-
Federal Court Dismisses Motion For A Fifth Generic To Be Added To Rivaroxaban Trial Of Common Issues Under PMNOC Regulations
...that the invalidity issues it raised be heard together with the trial against the first four generic manufacturers: Bayer v Dr. Reddy's, 2019 FC 1408. Prothonotary Tabib held that the circumstances were different from the previous motions. The Court stated that the addition of another party......
-
Federal Court dismisses motion for a fifth generic to be added to rivaroxaban trial of common issues under PMNOC Regulations
...that the invalidity issues it raised be heard together with the trial against the first four generic manufacturers: Bayer v Dr. Reddy’s, 2019 FC 1408. Prothonotary Tabib held that the circumstances were different from the previous motions. The Court stated that the addition of another party......